Preface to the 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 25, Issue SUPPL. 3, 1997, Pages

  Masur, Henry ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIMYCOBACTERIAL AGENT; ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CD4 ANTIGEN; CHICKENPOX VACCINE; CIDOFOVIR; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; CYTOCHROME P450; FAMCICLOVIR; FLUCONAZOLE; GANCICLOVIR; INFLUENZA VACCINE; INTERLEUKIN 2; ITRACONAZOLE; MEASLES MUMPS RUBELLA VACCINE; PENTAMIDINE; PLACEBO; PNEUMOCOCCUS VACCINE; PRIMAQUINE; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; RIFABUTIN; RITONAVIR; UNINDEXED DRUG; VALACICLOVIR;

BACTERIAL INFECTION; CANDIDIASIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; HERPES SIMPLEX; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MYCOBACTERIOSIS; NOTE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; T LYMPHOCYTE; TOXOPLASMOSIS; TUBERCULOSIS; VARICELLA ZOSTER VIRUS;

EID: 17644442423     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516251     Document Type: Note

References (14)

1. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21(suppl l):S32-43.
2. Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep 1995;44(RR-8):1-34.
3. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Ann Intern Med 1996; 124:348-68.
4. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis 1994; 18:421.
5. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995; 123:933-6.
6. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633-42.
7. Karon JM, Rosenberg PS, McQuillan G, Khara M, Gwinn M, Petersen LR. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA 1996;276:126-31.
8. Jones JL, Hanson DL, Ward JW, Kaplan JE. Incidence and trends in AIDS-related opportunistic illnesses in injecting drug users and men who have sex with men [abstract We.C.3418]. In: Program and abstracts of the 11th International Conference on AIDS (Vancouver, British Columbia, Canada). 1996.
9. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1997;25:S313-35.
10. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
11. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. The Multicenter Hemophilia Cohort Study. JAMA 1996; 276:105-10.
12. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. The International AIDS Society - USA. JAMA 1996; 276:146-54.
13. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996;335:1081-90.
14. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996;335:1091-8.